Cas:799262-38-7 2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid manufacturer & supplier

Chemical Name:2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid

CAS.NO:799262-38-7

Synonyms:2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid

Molecular Formula:C₁₀H₁₀N₄O₂

Molecular Weight:218.21200

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:450.3ºC at 760 mmHg

Density:1.4g/cm3

Index of Refraction:1.672

PSA:80.90000

Exact Mass:218.08000

LogP:0.59780

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid Use and application,2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid technical grade,usp/ep/jp grade.

Related News: Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. 2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid manufacturer The data will be updated at the upcoming 2019 ASH Annual Meeting next week. 2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid supplier Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid vendor Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 2-[4-(5-methyltetrazol-1-yl)phenyl]acetic acid factory Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data.